Nymox Reports Safety Monitoring Committee Findings for Pivotal Phase 3 NX-1207 Trials

28 July 2010, 7:00 am

HASBROUCK HEIGHTS, N.J. -- Nymox Pharmaceutical Corporation provided an update today on the Company's Phase 3 program for NX-1207, Nymox's investigational drug for benign prostatic hyperplasia .... Read More »

More Topics from "News"

• Premier Bay Area Luxury Real Estate Brokerage Launches New Real Estate Website
• Survey: Californians favor high-speed rail
• Menlo student wins two scholarships
• FA Cup starts in Staveley for Clarets Mad
• Gavin Hall Advances to Final 8 at USGA Jr. Amateur
• Scorecard: By the numbers
• Menlo Park firefighters want OT for preparation
• Meg Whitman Protest: Hundreds Of Nurses Protest Outside Of Candidates House
• Update: Atherton protest lasted 30 minutes